Posted by Michael Wonder on 03 Nov 2023
European Medicines Agency validates Pierre Fabre Laboratories' marketing authorisation application for combination Braftovi (encorafenib) and Mektovi (binimetinib) for patients with BRAF V600 mutant advanced non-small cell lung cancer
2 November 2023 - The application is based on results from the PHAROS study, which showed an objective response rate of 75% in treatment naïve patients and 46% in previously treated patients.
Pierre Fabre Laboratories announced today that the EMA validated the submission for Braftovi (encorafenib) + Mektovi (binimetinib) for the treatment of adult patients with BRAF V600 mutant advanced non-small cell lung cancer, who are either treatment naïve or have received prior therapy.
